Genetic polymorphisms in drug-metabolizing enzymes and drug targets

Molecular Genetics and Metabolism

Volumn 73, Issue 4, 2001, Pages 298-305

  Hiratsuka, Masahiro ^a   Mizugaki, Michinao ^a  

^a TOHOKU UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; ALDEHYDE DEHYDROGENASE; BETA 2 ADRENERGIC RECEPTOR; CHOLESTEROL ESTER TRANSFER PROTEIN; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DIHYDROPYRIMIDINE DEHYDROGENASE; DIPEPTIDYL CARBOXYPEPTIDASE; DOPAMINE RECEPTOR; DRUG METABOLIZING ENZYME; SEROTONIN RECEPTOR; THIOPURINE METHYLTRANSFERASE;

DRUG DISPOSITION; DRUG EFFICACY; DRUG EXPOSURE; DRUG METABOLISM; DRUG TARGETING; GENETIC POLYMORPHISM; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 0034841878     PISSN: 10967192     EISSN: None     Source Type: Journal    
DOI: 10.1006/mgme.2001.3204     Document Type: Article

References (91)

1. Cloning and expression of complementary DNAs for multiple members of the hu man cytochrome P 450IIC subfamily
2. Biochemistry and molecular biology of the human CYP2C subfamily
3. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese
4. Allelic variants of human cytochrome P450 2C9: Baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms
5. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism
6. Impaired (S)-warfarin metabolism catalysed by the R 144C allelic variant of CYP2C9
7. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy
8. Geographical/Interracial differences in polymorphic drug oxidation: Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19
9. A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin
10. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese
11. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans
12. Clinical significance of the sparteine/debrisoquine oxidation polymorphism
13. The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine
14. Debrisoquine/sparteine hydroxylation genotype and phenotype: Analysis of common mutations and alleles of CYP2D6 in a European population
15. Nomenclature for human CYP2D6 alleles
16. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations
17. Evidence for polymorphic oxidation of sparteine in Japanese subjects
18. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese
19. Metoprolol oxidation polymorphism in a Korean population: Comparison with native Japanese and Chinese populations
20. A new variant CYP2D6 allele (CYP2D6*21) with a single base insertion in exon 5 in a Japanese population associated with a poor metabolizer phenotype
21. Human cytochrome P450ILA3: cDNA sequence, role of the enzyme in the metabolic activation of promutagens, comparison to nitrosamine activation by human cytochrome P450IIE1
22. Five of 12 forms of vaccinia virus-expressed human hepatic cytochrome P450 metabolically activate aflatoxin B1
23. A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6
24. Comparison of a novel thin-layer chromatographic-fluorescence detection method with a spectrofluorometric method for the determination of 7-hydroxycoumarin in human urine
25. Interindividual variability of coumarin 7-hydroxylation in healthy volunteers
26. Interindividual variability of coumarin 7-hydroxylation in a Turkish population
27. Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity
28. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes
29. A genetic polymorphism in coumarin 7-hydroxylation: Sequence of the human CYP2A genes and identification of variant CYP2A6 alleles
30. A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502)
31. Genetic polymorphism of drug metabolizing enzymes: New mutations in CYP2D6 and CYP2A6 genes in Japanese
32. A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride in humans
33. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population
34. Roles of cytochrome b5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes
35. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4
36. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity
37. N-acetyltransferase
38. N-acetylation pharmacogenetics
39. Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferases from human liver
40. Human arylamine N-acetyltransferase genes: Isolation, chromosomal localization, and functional expression
41. Genotyping of N-acetylation polymorphism and correlation with procainamide metabolism
42. Human kidney thiopurine methyltransferase. Purification and biochemical properties
43. Purine substrates for human thiopurine methyltransferase
44. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity
45. Thiopurine methyltransferase activity in American white subjects and black subjects
46. Genetic polymorphism of thiopurine S-methyltransferase: Clinical importance and molecular mechanisms
47. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase
48. Thiopurine S-methyltransferase deficiency: Two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians
49. Human thiopurine methyltransferase pharmacogenetics: Kindred with a terminal exon splice junction mutation that results in loss of activity
50. Detection of known and new mutations in the thiopurine S-methyltransferase gene by single-strand conformation polymorphism analysis
51. Polymorphism of the thiopurine S-methyltransferase gene in African-Americans
52. Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance
53. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations
54. Thiopurine methyltransferase alleles in British and Ghanaian populations
55. Ethnic differences in thiopurine methyltransferase pharmacogenetics: Evidence for allele specificity in Caucasian and Kenyan individuals
56. Genetic analysis of thiopurine methyltransferase polymorphism in a Japanese population
57. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile
58. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy
59. Population study of dihydropyrimidine dehydrogenase in cancer patients
60. Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects
61. Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer
62. Structural organization of the human dihydropyrimidine dehydrogenase gene
63. Characterization of the human dihydropyrimidine dehydrogenase gene
64. Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity
65. Nomenclature for human DPYD alleles
66. Known variant DPYD alleles do not explain DPD deficiency in cancer patients
67. Molecular abnormality of an inactive aldehyde dehydrogenase variant commonly found in Orientals
68. Cloning of cDNAs for human aldehyde dehydrogenases 1 and 2
69. Racial differences in alcohol sensitivity: A new hypothesis
70. Effects of changing glutamate 487 to lysine in rat and human liver mitochondrial aldehyde dehydrogenase: A model to study human (Oriental type) class 2 aldehyde dehydrogenase
71. Genotypes for aldehyde dehydrogenase deficiency and alcohol sensitivity. The inactive ALDH2(2) allele is dominant
72. Metabolic and genetic control of HDL cholesterol levels
73. Alcohol intake modulates the effect of a polymorphism of the cholesteryl ester transfer protein gene on plasma high density lipoprotein and the risk of myocardial infarction
74. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis: The Regression Growth Evaluation Statin Study Group
75. DNA polymorphism at the locus for human cholesteryl ester transfer protein (CETP) is associated with high density lipoprotein cholesterol and apolipoprotein levels
76. Heterogeneity at the CETP gene locus: Influence on plasma CETP concentrations and HDL cholesterol levels
77. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels
78. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels
79. Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure
80. Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects
81. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties
82. Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells
83. Serotonin, schizophrenia, and antipsychotic drug action
84. Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia
85. Genetic variation of 5-HT2A receptor and response to clozapine
86. Genetic variation of the 5-HT2A receptor and response to clozapine
87. 5-HT2 receptor gene locus: Association with schizophrenia or treatment response not detected
88. Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine
89. The D5 dopamine receptor gene in schizophrenia: Identification of a nonsense change and multiple missense changes but lack of association with disease
90. Scanning of the dopamine D1 and D5 receptor genes by REF in neuropsychiatric patients reveals a novel missense change at a highly conserved amino acid
91. Functional analysis of the human D-5 dopamine receptor missense and nonsense variants: Differences in dopamine binding affinities